The FY22 Defense Appropriations Act provides funding to the Department of Defense Neurofibromatosis Research Program (NFRP) to support innovative, high-impact neurofibromatosis (NF) research. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
FY22 NFRP funding opportunities can be found here.
The Letter of Intent (pre-application) to indicate interest in applying to any of the six mechanisms will end on June 30, 2022.
